ANK3 and cancer: Our study found that ANK3 low expression was highly correlated with better cancer disease-specific survival (DSS), overall patient survival (OS) and progression-free survival (PFS) in adrenocortical carcinoma (ACC), colon cancer (COAD), kidney clear cell carcinoma (KIRC) and head and neck squamous cell carcinoma (HNSC).